AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
24 October 2026 · filed under 992238f27539
Pathos, an artificial intelligence drug development company, has raised $237 million in new financing, according to STAT News. The round pushes the company’s valuation to $3 billion.
STAT News reports the deal links three parties: a large dataset held by Tempus, AI-driven analysis provided by Pathos, and drug development capacity from Bristol Myers Squibb. The arrangement is structured so that Tempus’s data resources feed into Pathos’s computational analysis, with Bristol Myers Squibb positioned to carry resulting candidates through development.
The financing represents one of the larger recent capital raises in the AI-for-drug-discovery sector, reflecting investor interest in combining large clinical and molecular datasets with machine learning analysis to identify drug candidates. Pathos’s valuation increase to $3 billion places it among the better-capitalized companies operating in this space.
STAT News’s reporting frames the deal as an example of the convergence between data companies, AI analysis firms, and established pharmaceutical developers, a structure increasingly visible in the industry as companies seek to combine specialized capabilities rather than build each function in-house.
No additional financial terms, investor names, or timeline details beyond the valuation figure and raise amount are included in the available reporting.